Drugs / Insulin degludec/liraglutide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03175120 | May 2017 → Mar 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin degludec/liraglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03175120 ↗ |
| Route | Subcutaneous | “Administered subcutaneously (s.c., under the skin)” NCT03175120 ↗ |